论文部分内容阅读
探讨全身辅助化疗对非糖尿病乳腺癌患者血糖、血脂代谢的影响。选取2013年5月至2016年4月于嵊州市人民医院住院行辅助化疗的173例乳腺癌术后患者,所有患者临床资料完整,病理诊断明确,空腹血糖、血脂正常。观察并比较辅助化疗前后血糖、胆固醇及甘油三酯的变化情况,并对比不同化疗周期、不同化疗方案、不同TNM(tumor node metastasis)分期间的差异。结果显示,158例患者完成研究,化疗后空腹血糖升高36例,甘油三酯升高24例,胆固醇升高27例。血糖和甘油三酯在化疗4周后分别为(5.68±0.57)mmol/L、(1.56±0.22)mmol/L,较化疗前升高(P<0.01),而总胆固醇在化疗结束后为(4.91±0.45)mmol/L,较化疗4周升高(P<0.01)。蒽环联合紫杉类化疗后患者的血糖(6.06±0.51)mmol/L和甘油三酯(1.80±0.27)mmol/L较单独应用蒽环类[(5.55±0.51)mmol/L、(1.57±0.16)mmol/L]或紫杉类[(5.66±0.46)mmol/L、(1.51±0.06)mmol/L]升高,差异有统计学意义(P<0.01),但总胆固醇的差异无统计学意义(P>0.05)。化疗前、后,不同TNM分期间血糖、胆固醇及甘油三酯的差异均无统计学意义(P>0.05)。非糖尿病乳腺癌患者接受辅助化疗后可能会发生血糖、血脂代谢异常,严重者可出现糖尿病、高脂血症,且随着化疗周期的增加而逐渐加重,联合应用蒽环和紫杉类药物时更为显著。
To investigate the effect of systemic adjuvant chemotherapy on blood glucose and lipid metabolism in non-diabetic breast cancer patients. 173 patients with postoperative breast cancer who underwent adjuvant chemotherapy in Shengzhou People’s Hospital from May 2013 to April 2016 were selected. All patients had complete clinical data, clear pathological diagnosis, fasting blood glucose and normal blood lipids. The changes of blood glucose, cholesterol and triglyceride before and after adjuvant chemotherapy were observed and compared. The differences between different chemotherapy cycles, different chemotherapy regimens and different TNM stages were compared. The results showed that 158 patients completed the study, after chemotherapy, fasting blood glucose in 36 cases, triglyceride increased in 24 cases, 27 cases of elevated cholesterol. Blood glucose and triglyceride were (5.68 ± 0.57) mmol / L and (1.56 ± 0.22) mmol / L respectively after 4 weeks of chemotherapy, which were significantly higher than those before chemotherapy (P <0.01) 4.91 ± 0.45) mmol / L, which was higher than that of the 4 weeks of chemotherapy (P <0.01). The blood glucose (6.06 ± 0.51) mmol / L and triglyceride (1.80 ± 0.27) mmol / L were significantly higher in patients with anthracycline combined with taxanes than in those treated with anthracycline [(5.55 ± 0.51) mmol / L, [1.57 ± 0.16) mmol / L] or taxane (5.66 ± 0.46 mmol / L, (1.51 ± 0.06) mmol / L], the difference was statistically significant (P <0.01) Significance (P> 0.05). There were no significant differences in blood glucose, cholesterol and triglyceride between before and after chemotherapy (P> 0.05). Non-diabetic breast cancer patients receiving adjuvant chemotherapy may be blood sugar, dyslipidemia, severe cases may have diabetes, hyperlipidemia, and with the increase of chemotherapy cycle and gradually increased, combined with anthracycline and taxane drugs More significant.